

Synthesis of novel lipophilic polyamines with cytotoxic activity

Ksenia A. Perevoshchikova, Artemiy I. Nichugovskiy, Alexandra K. Isagulieva, Nina G. Morozova, Igor V. Ivanov, Mikhail A. Maslov and Alexander A. Shtil

1. Experimental section

1.1. Chemistry

All column chromatography solvents were distilled before use. Thin layer chromatography was performed using pre-coated aluminum plates (Kieselgel 60 F₂₅₄, Merck), which were visualized with the phosphomolybdic acid–ceric sulfate reagent. Flash column chromatography (FC) was performed on Kieselgel 60 (40–63 μm, Merck). ¹H and ¹³C NMR spectra were recorded at 30°C with Bruker DPX-300, DPX-500, DPX-400, and DPX-600 instruments in CDCl₃, MeOH-d₄, and D₂O as solvents. The signals of SiMe₄ (δ = 0.00 ppm) and CDCl₃ (δ = 77.16 ppm) were used as internal references. The *J* values are given in Hz. Mass spectra were recorded on a high-resolution Q-TOF G6550A spectrometer (Agilent) with a Dual-ESI-Jetstream ionisation source or on a Finnigan MAT 900XL-TRAP spectrometer with electrospray ionization (ESI).

1.1.1. General procedure for synthesis of bromo derivatives **1a-e**

Triphenylphosphine (5.28 mmol) and tetrabromomethane (5.28 mmol) were added to a solution of diglycerides (2-*O*-ethyl-1-*O*-octadecyl-*rac*-glycerol, 2-*O*-ethyl-3-*O*-hexadecyl-*rac*-glycerol, 2-*O*-ethyl-3-*O*-tetradecyl-*rac*-glycerol, 3-*O*-dodecyl-2-*O*-ethyl-*rac*-glycerol, 2-*O*-ethyl-*rac*-glycerol) (3.52 mmol) in anhydrous dichloromethane (15 ml), and the reaction mixture was stirred for 3 h at 24 °C, quenched with methanol (10 ml) and stirred for additional 15 min. The solvents were removed under reduced pressure, and the residue was chromatographed on silica gel using light petroleum – ethyl acetate mixture (30:1) to give compounds **1a-e**.

1.1.1.1. 1-Bromo-1-deoxy-2-*O*-ethyl-3-*O*-octadecyl-*rac*-glycerol (**1a**)

Yield 89%. ¹H NMR (400 MHz, CDCl₃): δ 0.91 (t, *J* = 6.9 Hz, 3 H, (CH₂)₁₅CH₃), 1.25 (t, *J* = 7.0 Hz, 3 H, OCH₂CH₃), 1.30 (br. s, 30 H, (CH₂)₁₅CH₃), 1.54-1.64 (m, 2 H, OCH₂CH₂), 3.39-3.47 (m, 3 H, OCH₂CH₂, CHH_aBr), 3.47-3.69 (m, 6 H, CH₂OCH₂CH₂, CHH_bBr, CHOCH₂CH₃). ¹³C NMR (75 MHz): 14.23, 15.58, 22.81, 26.19, 29.49, 29.57, 29.70, 29.73, 29.80, 29.83, 32.05, 32.71, 65.84, 70.81, 71.86, 76.84. MS-ESI *m/z*: [M]⁺ calcd for C₂₃H₄₇BrO₂ 434.28, found 434.93

1.1.1.2. 1-Bromo-1-deoxy-2-*O*-ethyl-3-*O*-hexadecyl-*rac*-glycerol (**1b**)

Yield 98 %. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, *J* = 6.5 Hz, 3 H, (CH₂)₁₃CH₃), 1.20 (t, *J* = 7.0 Hz, 3 H, OCH₂CH₃), 1.25 (br.s, 26 H, (CH₂)₁₃CH₃), 1.48 – 1.60 (m, 2 H, OCH₂CH₂), 3.36 – 3.47 (m, 3 H, OCH₂CH₂, CHH_aBr), 3.45-3.70 (m, 6 H, CH₂OCH₂CH₂, CHH_bBr, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): 14.13, 15.54, 22.76, 26.20, 29.44, 29.54, 29.70, 29.73, 29.76, 29.79, 32.02, 32.61, 65.81, 70.97, 71.86, 77.95. HRMS-ESI *m/z*: [M+K]⁺ calcd for C₂₁H₄₃BrO₂ 445.2090, found 445.2084.

1.1.1.3. 1-Bromo-1-deoxy-2-*O*-ethyl-3-*O*-tetradecyl-*rac*-glycerol (**1c**)

Yield 82 %. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, *J* = 6.7 Hz, 3 H, (CH₂)₁₁CH₃), 1.20 (t, *J* = 7.0 Hz, 3 H, OCH₂CH₃), 1.24 (br.s, 22 H, (CH₂)₁₁CH₃), 1.45 – 1.66 (m, 2 H, OCH₂CH₂), 3.35 – 3.47 (m, 3 H, OCH₂CH₂, CHH_aBr), 3.47-3.70 (m, 6 H, CH₂OCH₂CH₂, CHH_bBr, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): 14.01, 15.38, 22.61, 26.01, 29.29, 29.37, 29.53, 29.59, 29.61,

31.86, 32.49, 65.64, 70.68, 71.67, 77.66. HRMS-ESI m/z : $[M+Na]^+$ calcd for $C_{19}H_{39}BrO_2$ 401.2031, found 401.2030.

1.1.1.4. 1-Bromo-1-deoxy-3-O-dodecyl-2-O-ethyl-rac-glycerol (1d)

Yield 94 %. 1H NMR (300 MHz, $CDCl_3$): δ 0.88 (t, $J = 6.7$ Hz, 3 H, $(CH_2)_9CH_3$), 1.14 – 1.50 (m, 21 H, $(CH_2)_9CH_3$; OCH_2CH_3), 1.50 – 1.62 (m, 2 H, OCH_2CH_2), 3.39–3.49 (m, 3 H, OCH_2CH_2 , CHH_aBr), 3.49–3.72 (m, 6 H, $CH_2OCH_2CH_2$, CHH_bBr , $CHOCH_2CH_3$). ^{13}C NMR (75 MHz, $CDCl_3$): 14.09, 15.46, 22.67, 26.07, 29.34, 29.44, 29.59, 29.60, 29.63, 29.65, 31.91, 32.67, 65.75, 70.76, 71.78, 77.71. HRMS-ESI m/z : $[M+Na]^+$ calcd for $C_{17}H_{35}BrO_2$ 373.1718, found 373.1711.

1.1.1.5. 1-Bromo-3-O-decyl-1-deoxy-2-O-ethyl-rac-glycerol (1e)

Yield 90 %. 1H NMR (300 MHz, $CDCl_3$): δ 0.88 (t, $J = 6.7$ Hz, 3 H, $(CH_2)_7CH_3$), 1.15 – 1.49 (m, 17 H, $(CH_2)_7CH_3$; OCH_2CH_3), 1.48 – 1.66 (m, 2 H, OCH_2CH_2), 3.39 – 3.49 (m, 3 H, OCH_2CH_2 , CHH_aBr), 3.49–3.73 (m, 6 H, $CH_2OCH_2CH_2$, CHH_bBr , $CHOCH_2CH_3$). ^{13}C NMR (75 MHz, $CDCl_3$): 14.08, 15.45, 22.66, 26.07, 29.30, 29.43, 29.55, 29.59, 31.89, 32.66, 65.75, 70.75, 71.78, 77.71. HRMS-ESI m/z : $[M+Na]^+$ calcd for $C_{15}H_{31}BrO_2$ 345.1405, found 345.1405.

1.1.2. General procedure for synthesis of lipophilic polyamines 3a-g by the Fukuyama reaction

Regioselectively protected polyamines (**2a-c**) (0.344 mmol), Cs_2CO_3 (0.517 mmol) were added to a solution of compounds **1a-e** (0.344 mmol) in anhydrous DMF (5 ml), and the reaction mixture was stirred for 25 h at 80 °C. After DMF was removed under reduced pressure, the residue was re-dissolved in CH_2Cl_2 (10 ml), and water (20 ml) was added. The organic layer was separated, and the water layer was extracted with CH_2Cl_2 (3×10 ml). The combined organic phase was washed with water (3×10 ml), then dried with Na_2SO_4 , filtered, and evaporated to dryness under reduced pressure. The product was isolated using column chromatography on silica gel (toluene—acetone, 10:1) to give compounds **3a-g**.

1.1.2.1. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-12-(2-nitrophenylsulfonylamino)-4,9-diazadodecane (3a)

Yield 33%. 1H NMR (500 MHz, $CDCl_3$): δ 0.88 (t, $J = 6.8$ Hz, 3 H, $(CH_2)_{15}CH_3$), 1.07 (t, $J = 7.0$ Hz, 3 H, OCH_2CH_3), 1.25 (br.s, 30 H, $(CH_2)_{15}CH_3$), 1.43 (br.s, 22 H, 2 $C(CH_3)_3$), $NCH_2(CH_2)_2CH_2N$, 1.48–1.56 (m, 2 H, OCH_2CH_2), 1.63–1.74 (m, 2 H) and 1.75–1.90 (m, 2 H, 2 $NCH_2CH_2CH_2N$), 3.04–3.18 (m, 8 H, 4 CH_2NBoc), 3.20–3.68 (m, 13 H, $CH_2OCH_2CH_2$, $CHOCH_2CH_3$, 3 NCH_2), 6.35 (br.s, 1 H, $NHCH_2$), 7.55–7.87 (m, 6 H) and 7.98–8.17 (m, 2 H, 2 C_6H_4). ^{13}C NMR (126 MHz, $CDCl_3$) 14.24, 15.66, 22.83, 26.23, 27.19, 28.55, 28.60, 28.86, 29.50, 29.64, 29.74, 29.80, 29.84, 32.07, 44.57, 47.01, 65.73, 70.55, 71.94, 77.55, 79.67, 80.02, 124.21, 131.22, 131.68, 132.65, 133.46, 133.89, 148.29, 155.58.

1.1.2.2. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethyloxy-3-hexadecyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-12-(2-nitrophenylsulfonylamino)-4,9-diazadodecane (3b)

Yield 30 %. 1H NMR (300 MHz, $CDCl_3$): δ 0.87 (t, $J = 6.7$ Hz, 3 H, $(CH_2)_{13}CH_3$), 1.06 (t, $J = 7.0$, 3 H, OCH_2CH_3), 1.24 (br.s, 26 H, $(CH_2)_{13}CH_3$), 1.42 (br.s, 22 H, 2 $C(CH_3)_3$), $NCH_2(CH_2)_2CH_2N$, 1.48–1.59 (m, 2 H, OCH_2CH_2), 1.59–1.74 (m, 2 H) and 1.75–1.89 (m, 2 H, 2 $NCH_2CH_2CH_2N$), 3.00–3.18 (m, 8 H, 4 CH_2NBoc), 3.18–3.67 (m, 13 H, $CH_2OCH_2CH_2$, $CHOCH_2CH_3$, 3 NCH_2), 6.37 (br.s, 1 H, $NHCH_2$), 7.55–7.85 (m, 6 H) and 7.95–8.15 (m, 2 H, 2 C_6H_4). ^{13}C NMR (75 MHz, $CDCl_3$) 14.23, 15.64, 22.61, 26.21, 27.16, 28.53, 28.58, 28.84, 29.48, 29.62, 29.78, 29.82, 32.05, 44.56, 46.86, 47.10, 47.35, 49.16, 65.71, 70.53, 71.92, 77.48, 79.61,

80.00, 124.08, 124.19, 131.17, 131.68, 132.64, 132.90, 133.46, 148.26, 148.32, 155.56. HRMS-ESI m/z: [M+K]⁺ calcd for C₅₃H₉₀N₆O₁₄S₂ 1137.5593, found 1137.5600.

1.1.2.3. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethoxy-3-tetradecyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-12-(2-nitrophenylsulfonylamino)-4,9-diazadodecane (3c)

Yield 17 %. ¹H NMR (300 MHz, CDCl₃): δ 0.85 (t, *J* = 6.8 Hz, 3 H, (CH₂)₁₁CH₃), 1.06 (t, *J* = 7.0 Hz, 3 H, OCH₂CH₃), 1.24 (br.s, 22 H, (CH₂)₁₁CH₃), 1.41 (br.s, 22 H, 2 C(CH₃)₃, NCH₂(CH₂)₂CH₂N), 1.48-1.58 (m, 2 H, OCH₂CH₂), 1.60-1.73 (m, 2 H) and 1.73-1.90 (m, 2 H, 2 NCH₂CH₂CH₂N), 3.00-3.19 (m, 8 H, 4 CH₂NBoc), 3.20-3.68 (m, 13 H, CH₂OCH₂CH₂, CHOCH₂CH₃, 3 NCH₂), 7.55-7.87 (m, 6 H) and 7.92-8.14 (m, 2 H, 2 C₆H₄). ¹³C NMR (75 MHz, CDCl₃) 14.18, 15.60, 22.76, 26.00, 26.16, 27.12, 28.48, 28.53, 28.84, 29.48, 29.56, 29.72, 29.76, 32.00, 43.66, 44.52, 46.86, 47.02, 49.20, 65.65, 70.49, 71.87, 77.36, 79.54, 79.93, 124.15, 131.08, 131.66, 132.64, 133.46, 133.78, 148.21, 155.51. HRMS-ESI m/z: [M+Na]⁺ calcd for C₅₁H₈₆N₆O₁₄S₂ 1093.5541, found 1093.5550.

1.1.2.4. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-3-dodecyloxy-2-ethoxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-12-(2-nitrophenylsulfonylamino)-4,9-diazadodecane (3d)

Yield 18 %. ¹H NMR (300 MHz, CDCl₃): δ 0.88 (t, *J* = 6.8 Hz, 3 H, (CH₂)₉CH₃), 1.07 (t, *J* = 7.0 Hz, 3 H, OCH₂CH₃), 1.25 (br.s, 18 H, (CH₂)₉CH₃), 1.43 (br.s, 22 H, 2 C(CH₃)₃, NCH₂(CH₂)₂CH₂N), 1.48-1.56 (m, 2 H, OCH₂CH₂), 1.63-1.74 (m, 2 H) and 1.75-1.90 (m, 2 H, 2 NCH₂CH₂CH₂N), 3.04-3.18 (m, 8 H, 4 CH₂NBoc), 3.20-3.68 (m, 13 H, CH₂OCH₂CH₂, CHOCH₂CH₃, 3 NCH₂), 7.55-7.87 (m, 6 H), 7.98-8.17 (m, 2 H, 2 C₆H₄). ¹³C NMR (75 MHz, CDCl₃): δ 14.17, 15.58, 22.74, 26.15, 27.10, 28.47, 28.52, 28.80, 29.41, 29.55, 29.69, 29.74, 31.98, 43.59, 44.49, 46.84, 47.05, 49.20, 65.64, 70.48, 71.85, 77.45, 79.52, 79.92, 124.15, 131.07, 131.65, 132.60, 133.45, 133.75, 148.20, 155.51. HRMS-ESI m/z: [M+Na]⁺ calcd for C₄₉H₈₂N₆O₁₄S₂ 1065.5228, found 1065.5239.

1.1.2.5. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-3-decyloxy-2-ethoxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-12-(2-nitrophenylsulfonylamino)-4,9-diazadodecane (3e)

Yield 22 %. ¹H NMR (300 MHz, CDCl₃): δ 0.88 (t, *J* = 6.8 Hz, 3 H, (CH₂)₇CH₃), 1.07 (t, *J* = 7.0 Hz, 3 H, OCH₂CH₃), 1.25 (br.s, 14 H, (CH₂)₇CH₃), 1.43 (br.s, 22 H, 2 C(CH₃)₃, NCH₂(CH₂)₂CH₂N), 1.48-1.56 (m, 2 H, OCH₂CH₂), 1.63-1.74 (m, 2 H) and 1.75-1.90 (m, 2 H, 2 NCH₂CH₂CH₂N), 3.04-3.18 (m, 8 H, 4 CH₂NBoc), 3.20-3.68 (m, 13 H, CH₂OCH₂CH₂, CHOCH₂CH₃, 3 NCH₂), 6.35 (br.s, 1 H, NHCH₂), 7.55-7.87 (m, 6 H), 7.98-8.17 (m, 2 H, 2 C₆H₄). ¹³C NMR (75 MHz, CDCl₃): 14.13, 15.54, 22.69, 26.10, 27.06, 28.42, 28.47, 28.71, 29.33, 29.49, 29.60, 29.63, 31.91, 43.41, 44.46, 46.79, 46.99, 49.21, 65.59, 70.42, 71.80, 77.40, 79.47, 79.86, 124.11, 130.77, 130.99, 131.65, 132.64, 133.47, 133.68, 148.14, 155.46. HRMS-ESI m/z: [M+Na]⁺ calcd for C₄₇H₇₈N₆O₁₄S₂ 1037.4915, found 1037.4927.

1.1.2.6. 4,8-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethoxy-3-octadecyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-11-(2-nitrophenylsulfonylamino)-4,8-diazaundecane (3f)

Yield 27 %. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, *J* = 6.7 Hz, 3 H, (CH₂)₁₇CH₃), 1.05 (t, *J* = 7.0 Hz, 3 H, OCH₂CH₃), 1.24 (br.s, 30 H, (CH₂)₁₅CH₃), 1.41 (s, 18 H, 2 C(CH₃)₃), 1.46-1.58 (m, 2 H, OCH₂CH₂), 1.58-1.74 (m, 4 H) and 1.74-1.88 (m, 2 H, 3 NCH₂CH₂CH₂N), 2.97-3.20 (m, 8 H, 4 CH₂NHBoc), 3.20-3.66 (m, 13 H, CH₂OCH₂CH₂, CHOCH₂CH₃, 3 NCH₂), 7.54-7.84 (m, 6 H), 7.94-8.05 (m, 1 H) and 8.05-8.15 (m, 1 H, 2 C₆H₄). ¹³C NMR (75 MHz, CDCl₃) 14.19, 15.60, 22.77, 26.17, 27.14, 28.49, 28.54, 28.77, 29.43, 29.58, 29.74, 29.78, 32.01, 43.57, 44.59, 44.91, 45.06, 46.86, 49.32, 65.65, 70.47, 71.87, 77.47, 79.70, 80.07, 124.16, 131.08, 131.66,

132.67, 133.47, 133.74, 148.21, 155.44. HRMS-ESI m/z: $[M+K]^+$ calcd for $C_{54}H_{92}N_6O_{14}S_2$ 1151.5750, found 1151.5765.

1.1.2.7. 3,6-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-8-(2-nitrophenylsulfonylamino)-3,6-diazaoctane (3g)

Yield 20 %. 1H NMR (300 MHz, $CDCl_3$): δ 0.88 (t, $J = 6.8$ Hz, 3 H, $(CH_2)_{17}CH_3$), 0.95-1.13 (m, 3 H, OCH_2CH_3), 1.27 (br.s, 30 H, $(CH_2)_{15}CH_3$), 1.43 (br.s, 18 H, 2 $C(CH_3)_3$), 1.49-1.57 (m, 2 H, OCH_2CH_2), 3.10-3.24 (m, 8 H, 4 CH_2NBoc), 3.24-3.63 (m, 13 H, $CH_2OCH_2CH_2$, $CHOCH_2CH_3$, 3 NCH_2), 7.52-7.89 (m, 6 H) and 7.96-8.15 (m, 2 H, 2 C_6H_4). ^{13}C NMR (75 MHz, $CDCl_3$) 14.24, 15.59, 22.83, 26.22, 28.50, 28.55, 29.50, 29.65, 29.80, 29.84, 32.07, 42.24, 42.88, 45.82, 49.87, 65.58, 70.51, 71.91, 77.36, 79.35, 124.14, 130.83, 131.08, 132.90, 133.55, 148.26, 155.93. HRMS-ESI m/z: $[M+K]^+$ calcd for $C_{51}H_{86}N_6O_{14}S_2$ 1109.5280, found 1109.5287.

1.1.3. General procedure for synthesis modified lipophilic polyamines 5a-g

Cesium carbonate (0.179 mmol) and bromoethane (0.597 mmol) were added to a solution of compounds **3a-g** (0.060 mmol) in anhydrous DMF (4 ml), and the reaction mixture was stirred for 5 h at 80 °C. After DMF was removed under reduced pressure, the residue was re-dissolved in dichloromethane (10 ml), and water (20 ml) was added. The organic layer was separated, and the water layer was extracted with dichloromethane (3×10 ml). The combined organic phase was washed with water (3×10 ml), then dried with Na_2SO_4 , filtered, and the solvent was evaporated to dryness under reduced pressure. The product was isolated by column chromatography on silica gel (toluene—acetone solvent system, 10:1) to obtain products **5a-g**.

1.1.3.1. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-12-[N-ethyl-N-(2-nitrophenylsulfonyl)amino]-4,9-diazadodecane (5a)

Yield 83%. 1H NMR (300 MHz, $CDCl_3$): δ 0.88 (t, 3 H, $J = 6.9$ Hz, $(CH_2)_{15}CH_3$), 1.07 (t, 3 H, $J = 7.0$ Hz, OCH_2CH_3), 1.14 (t, 3 H, $J = 7.1$ Hz, NCH_2CH_3), 1.26 (br.s, 30 H, $(CH_2)_{15}CH_3$), 1.41-1.48 (m, 22 H, 2 $C(CH_3)_3$, $NCH_2(CH_2)_2CH_2N$), 1.49-1.56 (m, 2 H, OCH_2CH_2), 1.75-1.90 (m, 4 H, 2 $NCH_2CH_2CH_2N$), 3.03-3.18 (m, 8H, 4 CH_2NBoc), 3.26-3.66 (m, 15 H, $CH_2OCH_2CH_2$, $CHOCH_2CH_3$, 4 NCH_2), 7.58-7.72 (m, 6 H) and 7.96-8.08 (m, 2 H, 2 C_6H_4). ^{13}C NMR (75 MHz, $CDCl_3$): δ 13.25, 14.04, 15.47, 22.62, 26.02, 28.40, 29.29, 29.43, 29.54, 31.86, 65.56, 70.41, 71.72, 79.42, 124.07, 130.59, 131.55, 133.34, 133.59, 148.10, 155.35. HRMS-ESI m/z: $[M+K]^+$ calcd for $C_{57}H_{98}N_6O_{14}S_2$ 1193.6220, found 1193.6235.

1.1.3.2. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethyloxy-3-hexadecyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-12-[N-ethyl-N-(2-nitrophenylsulfonyl)amino]-4,9-diazadodecane (5b)

Yield 90 %. 1H NMR (300 MHz, $CDCl_3$): 1H NMR (300 MHz, $CDCl_3$): δ 0.88 (t, 3 H, $J = 6.9$ Hz, $(CH_2)_{15}CH_3$), 1.02-1.18 (m, OCH_2CH_3 , NCH_2CH_3), 1.25 (br.s, 26 H, $(CH_2)_{13}CH_3$), 1.38-1.49 (m, 24 H, 2 $C(CH_3)_3$, $NCH_2(CH_2)_2CH_2N$, OCH_2CH_2), 1.67-1.91 (m, 4 H, 2 $NCH_2CH_2CH_2N$), 3.01-3.23 (m, 8H, 4 CH_2NBoc), 3.24-3.70 (m, 15 H, $CH_2OCH_2CH_2$, $CHOCH_2CH_3$, 4 NCH_2), 7.56-7.75 (m, 6 H) and 7.94-8.10 (m, 2 H, 2 C_6H_4). ^{13}C NMR (75 MHz, $CDCl_3$): δ 13.76, 14.17, 15.65, 22.78, 26.22, 27.17, 27.69, 28.60, 29.45, 29.61, 29.76, 29.81, 32.04, 42.37, 44.61, 44.92, 46.94, 49.36, 65.73, 70.71, 71.92, 77.35, 79.53, 124.19, 124.24, 130.81, 131.16, 131.62, 131.67, 133.47, 133.88, 148.36, 155.55. HRMS-ESI m/z: $[M+H]^+$ calcd for $C_{55}H_{94}N_6O_{14}S_2$ 1127.6358, found 1127.6374.

1.1.3.3. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethyloxy-3-tetradecyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-12-[N-ethyl-N-(2-nitrophenylsulfonyl)amino]-4,9-diazadodecane (5c)

Yield 91 %. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, 3 H, *J* = 6.9 Hz, (CH₂)₁₅CH₃), 1.07 (t, 3 H, *J* = 7.0 Hz, OCH₂CH₃), 1.12 (t, 3 H, *J* = 7.1 Hz, NCH₂CH₃), 1.25 (br.s, 22 H, (CH₂)₁₁CH₃), 1.39-1.47 (m, 22 H, 2 C(CH₃)₃, NCH₂(CH₂)₂CH₂N), 1.48-1.60 (m, 2 H, OCH₂CH₂), 1.68-1.89 (m, 4 H, 2 NCH₂CH₂CH₂N), 3.00-3.23 (m, 8H, 4 CH₂NBoc), 3.23-3.68 (m, 15 H, CH₂OCH₂CH₂, CHOCH₂CH₃, 4 NCH₂), 7.53-7.77 (m, 6 H) and 7.91-8.06 (m, 2 H, 2 C₆H₄). ¹³C NMR (75 MHz, CDCl₃): δ 13.57, 14.19, 15.62, 22.77, 26.22, 27.07, 27.58, 28.56, 29.44, 29.58, 29.74, 29.78, 32.01, 42.29, 44.51, 44.81, 46.80, 65.73, 70.57, 71.88, 77.58, 79.58, 124.19, 124.23, 130.75, 131.11, 131.66, 131.71, 133.47, 133.51, 133.76, 133.83, 148.21, 148.26, 155.54. HRMS-ESI *m/z*: [M+K]⁺ calcd for C₅₃H₉₀N₆O₁₄S₂ 1137.5593, found 1137.5595.

1.1.3.4. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-3-dodecyloxy-2-ethoxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-12-[N-ethyl-N-(2-nitrophenylsulfonyl)amino]-4,9-diazadodecane (5d)

Yield 73 %. ¹H NMR (500 MHz, CDCl₃): δ 0.88 (t, 3 H, *J* = 6.9 Hz, (CH₂)₁₅CH₃), 1.07 (t, 3 H, *J* = 7.0 Hz, OCH₂CH₃), 1.14 (t, 3 H, *J* = 7.1 Hz, NCH₂CH₃), 1.26 (br.s, 18 H, (CH₂)₉CH₃), 1.40-1.49 (m, 22 H, 2 C(CH₃)₃, NCH₂(CH₂)₂CH₂N), 1.49-1.56 (m, 2 H, OCH₂CH₂), 1.75-1.90 (m, 4 H, 2 NCH₂CH₂CH₂N), 3.03-3.18 (m, 8H, 4 CH₂NBoc), 3.26-3.66 (m, 15 H, CH₂OCH₂CH₂, CHOCH₂CH₃, 4 NCH₂), 7.58-7.72 (m, 6 H) and 7.96-8.08 (m, 2 H, 2 C₆H₄). ¹³C NMR (125 MHz, CDCl₃): δ 13.72, 14.22, 15.62, 22.78, 26.16, 27.02, 27.51, 28.54, 29.45, 29.58, 29.58, 29.67, 29.73, 32.01, 42.37, 44.74, 48.95, 65.72, 70.50, 71.87, 77.53, 79.57, 124.23, 130.75, 131.02, 131.11, 133.50, 133.70, 133.79, 148.15, 155.52. HRMS-ESI *m/z*: [M+K]⁺ calcd for C₅₁H₈₆N₆O₁₄S₂ 1109.5280, found 1109.5293.

1.1.3.5. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-3-decyloxy-2-ethyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-12-[N-ethyl-N-(2-nitrophenylsulfonyl)amino]-4,9-diazadodecane (5e)

Yield 69 %. ¹H NMR (500 MHz, CDCl₃): δ 0.88 (t, 3 H, *J* = 6.9 Hz, (CH₂)₁₅CH₃), 1.07 (t, 3 H, *J* = 7.0 Hz, OCH₂CH₃), 1.14 (t, 3 H, *J* = 7.1 Hz, NCH₂CH₃), 1.26 (br.s, 14 H, (CH₂)₇CH₃), 1.38-1.48 (m, 22 H, 2 C(CH₃)₃, NCH₂(CH₂)₂CH₂N), 1.48-1.56 (m, 2 H, OCH₂CH₂), 1.75-1.90 (m, 4 H, 2 NCH₂CH₂CH₂N), 3.03-3.18 (m, 8H, 4 CH₂NBoc), 3.20-3.68 (m, 15 H, CH₂OCH₂CH₂, CHOCH₂CH₃, 4 NCH₂), 7.58-7.72 (m, 6 H) and 7.96-8.08 (m, 2 H, 2 C₆H₄). ¹³C NMR (125 MHz, CDCl₃): δ 13.74, 14.22, 15.63, 22.78, 26.17, 27.04, 28.55, 29.43, 29.58, 29.68, 29.72, 32.00, 42.35, 44.74, 44.89, 65.72, 70.49, 71.87, 77.53, 79.56, 124.19, 124.23, 130.75, 131.03, 131.11, 131.69, 131.74, 133.50, 133.71, 133.79, 148.15, 148.21, 155.44, 155.58. HRMS-ESI *m/z*: [M+Na]⁺ calcd for C₄₉H₈₂N₆O₁₄S₂ 1065.5228, found 1065.5230.

1.1.3.6. 4,8-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-11-[N-ethyl-N-(2-nitrophenylsulfonyl)amino]-4,8-diazaundecane (5f)

Yield 89 %. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, 3 H, *J* = 6.7, (CH₂)₁₅CH₃), 1.07 (t, 3 H, *J* = 7.0, OCH₂CH₃), 1.12 (t, 3 H, *J* = 7.3, NCH₂CH₃), 1.24 (br.s, 30 H, (CH₂)₁₅CH₃), 1.42 (s, 18 H, 2 C(CH₃)₃), 1.47-1.59 (m, 2 H, OCH₂CH₂), 1.59-1.72 (m, 2 H) and 1.72-1.89 (m, 4 H, 3 NCH₂CH₂CH₂N), 2.98-3.21 (m, 8 H, 4 CH₂NHBoc), 3.21-3.68 (m, 15 H, CH₂OCH₂CH₂, CHOCH₂CH₃, 4 NCH₂), 7.53-7.73 (m, 6 H) and 7.91-8.08 (m, 2 H, 2 C₆H₄). ¹³C NMR (75 MHz, CDCl₃): δ 13.76, 14.17, 15.64, 22.78, 26.22, 27.15, 27.64, 28.60, 29.45, 29.61, 29.76, 29.81, 32.04, 42.36, 44.62, 44.82, 44.90, 45.24, 46.93, 49.35, 65.73, 70.71, 71.92, 77.58, 79.73, 124.19, 124.25, 130.82, 131.15, 131.63, 131.69, 133.43, 133.47, 133.87, 133.97, 148.32, 148.38, 155.49, 155.52. HRMS-ESI *m/z*: [M+H]⁺ calcd for C₅₆H₉₆N₆O₁₄S₂ 1141.6504, found 1141.6507.

1.1.3.7. 3,6-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)-N-(2-nitrophenylsulfonyl)amino]-8-[N-ethyl-N-(2-nitrophenylsulfonyl)amino]-3,6-diazaoctane (5g)

Yield 66 %. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, 3 H, *J* = 6.9, (CH₂)₁₅CH₃), 0.98-1.10 (m, 3 H, OCH₂CH₃), 1.14 (t, 3 H, *J* = 7.1, NCH₂CH₃), 1.25 (br.s, 30 H, (CH₂)₁₅CH₃), 1.36-1.61 (m, 20 H, 2 C(CH₃)₃, OCH₂CH₂), 3.19-3.73 (m, 23 H, CH₂OCH₂CH₂, CHOCH₂CH₃, 8 NCH₂), 7.54-7.74 (m, 6 H) and 7.95-8.11 (m, 2 H, 2 C₆H₄). ¹³C NMR (125 MHz, CDCl₃): δ 13.80, 14.22, 15.62, 22.80, 26.21, 28.53, 29.47, 29.63, 29.78, 29.82, 32.05, 43.14, 43.52, 45.53, 65.68, 70.60, 71.87, 77.33, 80.30, 124.16, 124.23, 130.80, 131.23, 131.36, 131.82, 133.50, 133.61, 148.27, 155.46. HRMS-ESI *m/z*: [M+K]⁺ calcd for C₅₃H₉₀N₆O₁₄S₂ 1137.5593, found 1137.5602.

1.1.4. General procedure for removal of 2-nitrophenylsulfonyl groups

Thiophenol (0.988 mmol) and potassium carbonate (0.988 mmol) were added to a solution of compounds **3a-g**, **5a-g** (0.049 mmol) in anhydrous DMF (2 ml). The reaction mixture was stirred for 40 min at 23 °C and then was filtered through Celite®. The organic solvent was removed under reduced pressure, and the residue was chromatographed on silica (CH₂Cl₂ – MeOH – 25% aq. ammonia, 8:1:0.1) to yield the products.

1.1.4.1. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethoxy-3-octadecyloxyprop-1-yl)amino]-12-ethylamino-4,9-diazadodecane

Yield 97%. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, 3 H, *J* = 6.8, (CH₂)₁₅CH₃), 1.19 (t, 3 H, *J* = 7.0, OCH₂CH₃), 1.24 (br.s, 33 H, (CH₂)₁₅CH₃, NCH₂CH₃), 1.38-1.49 (m, 24 H, NCH₂(CH₂)₂CH₂N, 2 C(CH₃)₃, OCH₂CH₂), 1.58-2.05 (m, 2 H, 2 NCH₂CH₂CH₂N), 2.52-2.92 (m, 8 H, 4 NHCH₂), 3.05-3.36 (m, 8 H, 4 CH₂NBoc), 3.36-3.78 (m, 7 H, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 14.14, 15.65, 22.79, 25.89, 26.20, 28.58, 28.61, 29.47, 29.57, 29.66, 29.79, 32.05, 43.62, 45.21, 47.18, 51.32, 65.73, 71.86, 79.51, 155.82. MS-ESI *m/z*: [M+H]⁺ calcd for C₄₅H₉₂N₄O₆ 784.701, found 785.725.

1.1.4.2. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethoxy-3-hexadecyloxyprop-1-yl)amino]-12-ethylamino-4,9-diazadodecane

Yield 92 %. ¹H NMR (300 MHz, CDCl₃): δ 0.87 (t, 3 H, *J* = 6.8, (CH₂)₁₅CH₃), 1.20 (t, 3 H, *J* = 7.0, OCH₂CH₃), 1.21-1.29 (m, 29 H, (CH₂)₁₃CH₃, NCH₂CH₃), 1.39-1.48 (m, 24 H, OCH₂CH₂, NCH₂(CH₂)₂CH₂N, 2 C(CH₃)₃), 1.66-1.98 (m, 4 H, 2 NCH₂CH₂CH₂N), 2.50-2.97 (m, 8 H, 4 NHCH₂), 3.10-3.33 (m, 8 H, 4 CH₂NBoc), 3.37-3.78 (m, 7 H, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 14.09, 15.53, 22.77, 25.90, 26.17, 28.40, 28.44, 29.45, 29.57, 29.67, 29.72, 29.79, 32.03, 43.46, 45.16, 47.18, 51.02, 65.73, 71.96, 79.32, 155.78. HRMS-ESI *m/z*: [M+H]⁺ calcd for C₄₃H₈₈N₄O₆ 757.6782, found 757.6788.

1.1.4.3. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethoxy-3-tetradecyloxyprop-1-yl)amino]-12-ethylamino-4,9-diazadodecane

Yield 62 %. ¹H NMR (300 MHz, CDCl₃): δ 0.87 (t, 3 H, *J* = 6.8, (CH₂)₁₅CH₃), 1.13-1.22 (m, 6 H, OCH₂CH₃, NCH₂CH₃), 1.26 (br.s, 22 H, (CH₂)₁₁CH₃), 1.40-1.49 (m, 24 H, OCH₂CH₂, NCH₂(CH₂)₂CH₂N, 2 C(CH₃)₃), 1.61-1.90 (m, 4 H, 2 NCH₂CH₂CH₂N), 2.55-2.81 (m, 8 H, 4 NHCH₂), 3.03-3.35 (m, 8 H, 4 CH₂NBoc), 3.36-3.77 (m, 7 H, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 14.18, 15.81, 22.80, 26.07, 26.27, 28.61, 28.64, 29.47, 29.62, 29.75, 29.78, 29.81, 32.05, 44.04, 45.19, 47.02, 47.54, 51.59, 65.67, 71.86, 72.06, 77.70, 79.42, 155.80. HRMS-ESI *m/z*: [M+H]⁺ calcd for C₄₁H₈₄N₄O₆ 729.6470, found 729.6481.

1.1.4.4. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-3-dodecyloxy-2-ethoxyprop-1-yl)amino]-12-ethylamino-4,9-diazadodecane

Yield 81 %. ¹H NMR (300 MHz, CDCl₃): δ 0.87 (t, 3 H, *J* = 6.8, (CH₂)₁₅CH₃), 1.12-1.21 (m, 6 H, OCH₂CH₃, NCH₂CH₃), 1.25 (br.s, 18 H, (CH₂)₉CH₃), 1.37-1.47 (m, 24 H, OCH₂CH₂, NCH₂(CH₂)₂CH₂N, 2 C(CH₃)₃), 1.61-1.97 (m, 4 H, 2 NCH₂CH₂CH₂N), 2.50-2.91 (m, 8 H, 4 NHCH₂), 3.02-3.34 (m, 8 H, 4 CH₂NBoc), 3.34-3.76 (m, 7 H, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 14.24, 15.75, 22.79, 25.90, 26.18, 28.49, 28.55, 29.45, 29.57,

29.71, 29.77, 32.01, 43.76, 45.27, 47.13, 51.57, 65.66, 71.80, 79.54, 155.70. HRMS-ESI m/z: [M+H]⁺ calcd for C₃₉H₈₀N₄O₆ 701.6156, found 701.6160.

1.1.4.5. 4,9-Bis(tert-butyloxycarbonyl)-1-[N-(rac-3-decyloxy-2-ethoxyprop-1-yl)amino]-12-ethylamino-4,9-diazadodecane

Yield 73 %. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, 3 H, *J* = 6.8, (CH₂)₁₅CH₃), 1.17 (t, 3 H, *J* = 7.0, OCH₂CH₃), 1.19-1.27 (m, 17 H, (CH₂)₇CH₃, NCH₂CH₃), 1.45-1.54 (m, 24 H, OCH₂CH₂, NCH₂(CH₂)₂CH₂N, 2 C(CH₃)₃), 1.58-1.97 (m, 4 H, 2 NCH₂CH₂CH₂N), 2.53-2.89 (m, 8 H, 4 NHCH₂), 3.05-3.34 (m, 8 H, 4 CH₂NBoc), 3.34-3.78 (m, 7 H, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 14.23, 15.75, 22.77, 25.63, 26.18, 28.50, 28.55, 29.42, 29.56, 29.66, 29.70, 31.99, 43.80, 46.58, 47.14, 51.60, 65.65, 71.79, 79.52, 155.88. HRMS-ESI m/z: [M+H]⁺ calcd for C₃₇H₈₈N₄O₆ 673.5843, found 673.5854.

1.1.4.6. 4,8-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethoxy-3-octadecyloxyprop-1-yl)amino]-11-ethylamino-4,8-diazaundecane

Yield 84 %. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, 3 H, *J* = 7.0, (CH₂)₁₃CH₃), 1.11-1.22 (m, 6 H, NCH₂CH₃, OCH₂CH₃), 1.24 (br.s., 30H, (CH₂)₁₅CH₃), 1.43 (br.s, 18 H, 2 C(CH₃)₃), 1.47-1.61 (m, 2 H, OCH₂CH₂), 1.62-1.84 (m, 6 H, 3 NCH₂CH₂CH₂N), 2.53-2.79 (m, 8 H, 4 NHCH₂), 3.08-3.33 (m, 8 H, 4 CH₂NBoc), 3.36-3.76 (m, 7 H, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 14.21, 15.80, 22.80, 26.24, 28.59, 28.61, 29.47, 29.61, 29.75, 29.77, 29.81, 32.04, 44.11, 45.06, 47.60, 51.61, 65.66, 71.82, 72.00, 77.71, 79.51, 155.65. HRMS-ESI m/z: [M+H]⁺ calcd for C₄₄H₉₀N₄O₆ 771.6939, found 771.6949.

1.1.4.7. 3,6-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethoxy-3-octadecyloxyprop-1-yl)amino]-8-ethylamino-3,6-diazaoctane

Yield 84 %. ¹H NMR (300 MHz, CDCl₃): δ 0.88 (t, 3 H, *J* = 6.8, (CH₂)₁₅CH₃), 1.20 (t, 3 H, *J* = 7.0, OCH₂CH₃), 1.28 (br.s, 33 H, (CH₂)₁₅CH₃, NCH₂CH₃), 1.47 (br.s, 18 H, 2 C(CH₃)₃), 1.52-1.60 (m, 2 H, OCH₂CH₂), 2.53-3.03 (m, 8 H, 4 NHCH₂), 3.20-3.77 (m, 15 H, 4 CH₂NBoc, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 14.22, 15.81, 22.81, 26.25, 28.61, 29.48, 29.62, 29.77, 29.82, 32.05, 46.19, 47.78, 47.86, 48.37, 51.45, 65.68, 71.84, 77.82, 80.09, 155.66. HRMS-ESI m/z: [M+H]⁺ calcd for C₄₁H₈₄N₄O₆ 729.6469, found 729.6471.

1.1.4.8. 4,9-Bis(tert-butyloxycarbonyl)-1-(rac-2-ethoxy-3-octadecyloxyprop-1-yl)amino-12-amino-4,9-diazadodecane

Yield 72%. ¹H NMR (300 MHz, CDCl₃): δ 0.88 (t, *J* = 6.8 Hz, 3 H, (CH₂)₁₅CH₃), 1.19 (t, *J* = 7.0 Hz, 3 H, OCH₂CH₃), 1.25 (br.s, 30 H, (CH₂)₁₅CH₃), 1.39-1.47 (m, 22 H, 2 C(CH₃)₃, NCH₂(CH₂)₂CH₂N), 1.48-1.56 (m, 2 H, OCH₂CH₂), 1.63-1.74 (m, 2 H) and 1.75-1.90 (m, 2 H, 2 NCH₂CH₂CH₂N), 2.52-2.93 (m, 6 H, CH₂NHCH₂, CH₂NH₂), 3.04-3.37 (m, 8 H, 4 CH₂NBoc), 3.37-3.78 (m, 7 H, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 14.23, 15.78, 22.81, 25.81, 26.24, 28.60, 29.48, 29.62, 29.81, 32.05, 45.33, 46.93, 51.64, 65.70, 71.88, 79.82, 155.81. HRMS-ESI m/z: [M+H]⁺ calcd for C₄₃H₈₈N₄O₆ 757.6782, found 757.6781.

1.1.4.9. 4,9-Bis(tert-butyloxycarbonyl)-1-[(rac-2-ethoxy-3-hexadecyloxyprop-1-yl)amino]-12-amino-4,9-diazadodecane

Yield 71 %. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, *J* = 6.7 Hz, 3 H, (CH₂)₁₃CH₃), 1.19 (t, *J* = 7.0, 3 H, OCH₂CH₃), 1.28 (br.s, 26 H, (CH₂)₁₃CH₃), 1.41-1.48 (m, 22 H, 2 C(CH₃)₃, NCH₂(CH₂)₂CH₂N), 1.50-1.59 (m, 2 H, OCH₂CH₂), 1.59-1.78 (m, 4 H, 2 NCH₂CH₂CH₂N), 2.51-2.63 (m, 2H) and 2.63-2.79 (m, 4 H, CH₂NHCH₂, CH₂NH₂), 3.04-3.33 (m, 8 H, 4 CH₂NBoc), 3.35-3.77 (m, 7 H, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 14.25, 15.80, 22.82, 25.80, 26.24, 28.60, 29.48, 29.61, 29.78, 29.82, 32.05, 49.89, 46.74, 51.59, 65.69, 71.83, 71.94, 79.49, 155.72. HRMS-ESI m/z: [M+H]⁺ calcd for C₄₁H₈₄N₄O₆ 729.6469, found 729.6471.

1.1.4.10. 4,8-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)amino]-11-amino-4,8-diazaundecane

Yield 63 %. ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, *J* = 6.8 Hz, 3 H, (CH₂)₁₅CH₃), 1.14-1.235 (m, 30 H, (CH₂)₁₅CH₃, OCH₂CH₃), 1.40-1.49 (m, 22 H, 2 C(CH₃)₃, NCH₂(CH₂)₂CH₂N), 1.63-1.94 (m, 2 H, OCH₂CH₂), 1.63-1.94 (m, 6 H, 3 NCH₂CH₂CH₂N), 2.49-2.92 (m, 6 H, CH₂NHCH₂, CH₂NH₂), 3.02-3.35 (m, 8 H, 4 CH₂NBoc), 3.36-3.49 (m, 4 H), 3.49-3.62 (m, 1 H), 3.63-3.77 (m, 2 H, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 14.23, 15.76, 22.81, 26.23, 28.32, 28.60, 29.48, 29.62, 29.77, 29.83, 32.05, 45.11, 65.71, 71.91, 79.78, 155.68.

1.1.4.11. 3,6-Bis(tert-butyloxycarbonyl)-1-[N-(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)amino]-8-amino-3,6-diazaoctane

Yield 84 %. ¹H NMR (300 MHz, CDCl₃): δ 0.88 (t, 3 H, *J* = 6.7 Hz, (CH₂)₁₅CH₃), 1.19 (t, 3 H, *J* = 7.0 Hz, OCH₂CH₃), 1.25 (br.s, 30 H, (CH₂)₁₅CH₃), 1.46 (br.s, 18 H, 2 C(CH₃)₃), 1.51-1.60 (m, 2 H, OCH₂CH₂), 2.63-2.92 (m, 6 H, CH₂NHCH₂, CH₂NH₂), 3.17-3.38 (m, 8 H, 4 CH₂NBoc), 3.38-3.75 (m, 7 H, CH₂OCH₂CH₂, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 13.98, 15.62, 22.64, 25.87, 26.03, 28.28, 28.54, 29.20, 29.31, 29.44, 29.53, 29.60, 29.66, 31.89, 42.02, 45.86, 47.80, 54.89, 65.58, 77.37, 79.01, 155.50. MS-ESI *m/z*: [M+H]⁺ calcd for C₃₉H₈₀N₄O₆ 701.62, found 701.97.

1.1.5. General procedure for Boc-deprotection

A solution of 3 *N* HCl in anhydrous dioxane (1 ml) was added to a pre-cooled (4 °C) solution of Boc-derivatives (0.048 mmol) in anhydrous dichloromethane (2 ml). After the reaction mixture was stirred for 2 h at 23 °C, the volatiles were removed under reduced pressure, and the residue was re-crystallized from diethyl ether (4 ml) to afford final products as beige or white flakes.

1.1.5.1. 12-Ethylamino-1-[(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (6a)

Yield (97 %). ¹H NMR (500 MHz, CDCl₃-CD₃OD): δ 0.86 (t, 3 H, *J* = 6.8, (CH₂)₁₅CH₃), 1.24-1.31 (m, 36 H, (CH₂)₁₅CH₃, OCH₂CH₃, NCH₂CH₃), 1.51-1.61 (m, 2 H, OCH₂CH₂), 1.78-1.87 (m, 4 H, NCH₂(CH₂)₂CH₂N), 2.08-2.24 (m, 4 H, 2 NCH₂CH₂CH₂N), 3.00-3.23 (m, 16 H, 8 CH₂NH), 3.40-3.54 (m, 2 H, OCH₂CH₂) and (1 H, OCHH_bCH), 3.54-3.64 (m, 1 H, OCHH_bCH₃) and (1 H, OCHH_aCH), 3.70-3.79 (m, 1 H, OCHH_bCH₃), 3.80-3.88 (m, 1 H, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 11.43, 14.65, 15.72, 23.49, 23.65, 23.70, 23.82, 26.78, 30.14, 30.24, 30.33, 30.55, 30.61, 32.81, 44.06, 44.90, 45.58, 45.64, 46.01, 48.06, 49.96, 66.64, 70.82, 72.63, 74.78. HRMS-ESI *m/z*: [M+H]⁺ calcd for C₃₅H₇₆N₄O₂ 585.6047, found 585.6044.

1.1.5.2. 12-Ethylamino-1-[(rac-2-ethyloxy-3-hexadecyloxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (6b)

Yield 72 %. ¹H NMR (600 MHz, CD₃OD-D₂O): δ 0.88 (t, 3 H, *J* = 6.8, (CH₂)₁₃CH₃), 1.22 (t, 3 H, *J* = 7.0, NCH₂CH₃) 1.25-1.33 (m, 29 H, (CH₂)₁₃CH₃, OCH₂CH₃), 1.50-1.61 (m, 2 H, OCH₂CH₂), 1.77-1.89 (m, 4 H, NCH₂(CH₂)₂CH₂N), 2.08-2.25 (m, 4 H, 2 NCH₂CH₂CH₂N), 3.06-3.27 (m, 16 H, 8 CH₂NH), 3.44-3.54 (m, 2 H, OCH₂CH₂) and (1 H, OCHH_bCH), 3.57-3.69 (m, 1 H, OCHH_bCH₃) and (1 H, OCHH_aCH), 3.72-3.80 (m, 1 H, OCHH_bCH₃), 3.83-3.91 (m, 1 H, CHOCH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 11.51, 14.54, 15.69, 23.46, 23.69, 23.84, 23.88, 26.75, 30.11, 30.14, 30.23, 30.43, 30.45, 32.75, 44.12, 45.00, 45.65, 45.96, 48.08, 50.00, 66.61, 70.52, 72.72, 74.76. HRMS-ESI *m/z*: [M+H]⁺ calcd for C₃₃H₇₃N₄O₂ 557.5734, found 557.5728.

1.1.5.3. 12-Ethylamino-1-[(rac-2-ethyloxy-3-tetradecyloxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (6c)

Yield 92 %. ¹H NMR (600 MHz, CD₃OD-D₂O): δ 0.88 (t, 3 H, *J* = 6.8, (CH₂)₁₁CH₃), 1.25 (t, 3 H, *J* = 7.0, NCH₂CH₃) 1.29 (br.s, 22 H, (CH₂)₁₁CH₃), 1.36 (t, 3 H, *J* = 7.3, OCH₂CH₃), 1.56-

1.64 (m, 2 H, OCH₂CH₂), 1.83-1.94 (m, 4 H, NCH₂(CH₂)₂CH₂N), 2.14-2.28 (m, 4 H, 2 NCH₂CH₂CH₂N), 3.07-3.30 (m, 16 H, 8 CH₂NH), 3.47-3.59 (m, 2 H, OCH₂CH₂) and (1 H, OCHH_bCH), 3.60-3.69 (m, 1 H, OCHH_bCH₃) and (1 H, OCHH_aCH), 3.76-3.83 (m, 1 H, OCHH_bCH₃), 3.85-3.90 (m, 1 H CH₂CH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 11.50, 14.32, 15.67, 23.45, 23.79, 24.00, 24.07, 26.88, 30.10, 30.25, 30.30, 30.39, 30.41, 32.76, 44.23, 45.23, 45.82, 46.16, 48.20, 50.36, 66.56, 70.57, 72.89, 74.84. HRMS-ESI m/z: [M+H]⁺ calcd for C₃₁H₆₉N₄O₂ 529.5421, found 529.5415.

1.1.5.4. 1-[(rac-3-Dodecyloxy-2-ethoxyprop-1-yl)amino]-12-ethylamino-4,9-diazadodecane tetrahydrochloride (6d)

Yield 94 %. ¹H NMR (300 MHz, CD₃OD-D₂O): δ 0.86 (t, 3 H, *J* = 6.8, (CH₂)₉CH₃), 1.15-1.38 (m, 24 H, NCH₂CH₃, (CH₂)₉CH₃, OCH₂CH₃), 1.49-1.63 (m, 2 H, OCH₂CH₂), 1.76-1.91 (m, 4 H, NCH₂(CH₂)₂CH₂N), 2.06-2.28 (m, 4 H, 2 NCH₂CH₂CH₂N), 3.02-3.28 (m, 16 H, 8 CH₂NH), 3.44-3.57 (m, 2 H, OCH₂CH₂) and (1 H, OCHH_bCH), 3.57-3.79 (m, 3 H, OCHH_bCH₃, OCHH_aCH, OCHH_bCH₃), 3.79-3.90 (m, 1 H CH₂CH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 11.36, 14.21, 15.51, 23.11, 23.51, 23.69, 23.78, 26.44, 29.68, 29.80, 29.98, 32.37, 44.06, 44.93, 45.60, 45.93, 48.04, 50.02, 66.50, 70.26, 72.73, 74.52. HRMS-ESI m/z: [M+H]⁺ calcd for C₂₉H₆₅N₄O₂ 501.5108, found 501.5102.

1.1.5.5. 1-[(rac-3-Decyloxy-2-ethoxyprop-1-yl)amino]-12-ethylamino-4,9-diazadodecane tetrahydrochloride (6e)

Yield 65 %. ¹H NMR (300 MHz, CD₃OD-D₂O): δ 0.86 (t, 3 H, *J* = 6.8, (CH₂)₇CH₃), 1.13-1.36 (m, 24 H, NCH₂CH₃, (CH₂)₇CH₃, OCH₂CH₃), 1.50-1.63 (m, 2 H, OCH₂CH₂), 1.77-1.91 (m, 4 H, NCH₂(CH₂)₂CH₂N), 2.08-2.27 (m, 4 H, 2 NCH₂CH₂CH₂N), 3.05-3.29 (m, 16 H, 8 CH₂NH), 3.46-3.58 (m, 2 H, OCH₂CH₂) and (1 H, OCHH_bCH), 3.58-3.70 (m, 1 H, OCHH_bCH₃) and (1 H, OCHH_aCH), 3.70-3.82 (m, 1 H, OCHH_bCH₃), 3.82-3.90 (m, 1 H CH₂CH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 11.42, 14.24, 15.56, 23.20, 23.61, 23.80, 23.90, 26.57, 29.80, 29.92, 29.94, 30.06, 30.10, 32.47, 44.12, 45.03, 45.68, 45.99, 48.11, 50.12, 66.53, 70.32, 72.80, 74.62. HRMS-ESI m/z: [M+H]⁺ calcd for C₂₇H₆₁N₄O₂ 473.4795, found 473.4789.

1.1.5.6. 11-Ethylamino-1-[(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)amino]-4,8-diazaundecane tetrahydrochloride (6f)

Yield 95 %. ¹H NMR (600 MHz, CD₃OD-D₂O): δ 0.88 (t, 3 H, *J* = 6.8, (CH₂)₁₅CH₃), 1.22 (t, 3 H, *J* = 7.0, NCH₂CH₃) 1.26 (br.s., 30 H, (CH₂)₁₅CH₃), 1.32 (t, 3 H, *J* = 7.3, OCH₂CH₃), 1.52-1.60 (m, 2 H, OCH₂CH₂), 2.10-2.24 (m, 6 H, 3 NCH₂CH₂CH₂N), 3.09-3.27 (m, 16 H, 8 CH₂NH), 3.47-3.56 (m, 2 H, OCH₂CH₂) and (1 H, OCHH_bCH), 3.57-3.69 (m, 1 H, OCHH_bCH₃) and (1 H, OCHH_aCH), 3.71-3.80 (m, 1 H, OCHH_bCH₃), 3.82-3.90 (m, 1 H CH₂CH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 11.37, 14.31, 15.56, 23.23, 23.56, 23.70, 23.87, 26.56, 29.84, 29.92, 29.97, 30.08, 30.11, 32.50, 44.07, 44.89, 45.71, 45.78, 45.92, 50.03, 66.54, 70.40, 72.75, 74.63. HRMS-ESI m/z: [M+H]⁺ calcd for C₃₄H₇₅N₄O₂ 571.5890, found 571.5878.

1.1.5.7. 8-Ethylamino-1-[(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)amino]-3,6-diazaoctane tetrahydrochloride (6g)

Yield 92 %. ¹H NMR (500 MHz, CDCl₃-CD₃OD): δ 0.86 (t, 3 H, *J* = 6.8, (CH₂)₁₅CH₃), 1.25 (br.s, 33 H, (CH₂)₁₅CH₃, NCH₂CH₃), 1.37 (t, 3 H, *J* = 7.1, OCH₂CH₃), 1.52-1.65 (m, 2 H, OCH₂CH₂), 3.06-3.25 (m, 16 H, 8 CH₂NH), 3.37-3.68 (m, 4 H, OCH₂CH₂, OCH₂CH, OCHH_aCH₃), 3.71-3.82 (m, 1 H, OCHH_bCH₃), 3.86-3.93 (m, 1 H CH₂CH₂CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 11.43, 14.57, 15.67, 23.38, 26.66, 30.00, 30.08, 30.16, 30.38, 32.68, 44.39, 44.63, 44.72, 45.57, 45.84, 45.98, 50.29, 66.65, 70.50, 72.69, 74.68. HRMS-ESI m/z: [M+H]⁺ calcd for C₃₁H₆₉N₄O₂ 529.5421, found 529.5415.

1.1.5.8. 12-Amino-1-[(rac-2-Ethoxy-3-octadecyloxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (7a)

Yield (99 %). ^1H NMR (500 MHz, CDCl_3 - CD_3OD): 0.88 (t, $J = 6.9$ Hz, 3 H, $(\text{CH}_2)_{15}\text{CH}_3$), 1.24 (t, $J = 7.0$ Hz, 3 H, OCH_2CH_3), 1.28 (br.s, 30 H, $(\text{CH}_2)_{15}\text{CH}_3$), 1.51-1.63 (m, 2 H, OCH_2CH_2), 1.78-1.96 (m, 4 H, $\text{NCH}_2(\text{CH}_2)_2\text{CH}_2\text{N}$), 2.05-2.15 (m, 2 H) and 2.15-2.25 (m, 2 H, 2 $\text{NCH}_2\text{CH}_2\text{CH}_2\text{N}$), 3.01-3.27 (m, 14 H, 7 CH_2NH), 3.52-3.71 (m, 4 H) and 3.71-3.86 (m, 3 H, $\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CHOCH}_2\text{CH}_3$). ^{13}C NMR (75 MHz, CDCl_3): δ 14.36, 15.54, 23.19, 23.61, 23.81, 23.76, 24.79, 26.44, 29.74, 29.78, 29.83, 29.91, 29.99, 32.42, 37.60, 39.90, 45.58, 45.87, 49.96, 66.53, 70.21, 72.72, 74.63. HRMS-ESI m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{33}\text{H}_{73}\text{N}_4\text{O}_2$ 557.5734, found 557.5728.

1.1.5.9. 12-Amino-1-[(rac-2-ethoxy-3-hexadecyloxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (7b)

Yield 98 %. ^1H NMR (300 MHz, CDCl_3 - CD_3OD): 0.87 (t, $J = 6.7$, 3 H, $(\text{CH}_2)_{13}\text{CH}_3$), 1.28 (br.s, 29 H, OCH_2CH_3 , $(\text{CH}_2)_{15}\text{CH}_3$), 1.49-1.63 (m, 2 H, OCH_2CH_2), 1.74-1.92 (m, 4 H, $\text{NCH}_2(\text{CH}_2)_2\text{CH}_2\text{N}$), 2.04-2.27 (m, 4 H, 2 $\text{NCH}_2\text{CH}_2\text{CH}_2\text{N}$), 3.02-3.29 (m, 14 H, 7 CH_2NH), 3.47-3.80 (m, 7 H $\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CHOCH}_2\text{CH}_3$). ^{13}C NMR (75 MHz, CDCl_3): δ 14.27, 15.48, 23.06, 23.53, 23.80, 24.79, 26.31, 29.54, 29.63, 29.73, 29.79, 32.27, 37.59, 39.90, 45.56, 45.80, 48.01, 49.94, 66.48, 69.97, 72.75, 74.50. HRMS-ESI m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{69}\text{N}_4\text{O}_2$ 529.5421, found 529.5419.

1.1.5.10. 11-Amino-1-[N-(rac-2-ethoxy-3-octadecyloxyprop-1-yl)amino]-4,8-diazaundecane tetrahydrochloride (7c)

Yield 89 %. ^1H NMR (300 MHz, CD_3OD - D_2O): 0.88 (t, $J = 6.9$ Hz, 3 H, $(\text{CH}_2)_{15}\text{CH}_3$), 1.22 (t, $J = 7.0$ Hz, 3 H, OCH_2CH_3), 1.27 (br.s, 30 H, $(\text{CH}_2)_{15}\text{CH}_3$), 1.52-1.62 (m, 2 H, OCH_2CH_2), 2.06-2.26 (m, 6 H, 2 $\text{NCH}_2\text{CH}_2\text{CH}_2\text{N}$), 3.07-3.27 (m, 14 H, 7 CH_2NH), 3.45-3.55 (m, 3 H), 3.57-3.70 (m, 2 H), 3.72-3.80 (m, 1H) and 3.84-3.90 (m, 1 H, $\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CHOCH}_2\text{CH}_3$). ^{13}C NMR (75 MHz, CDCl_3): δ 14.68, 15.72, 23.51, 23.67, 23.76, 24.82, 26.76, 30.10, 30.24, 30.30, 30.57, 32.81, 37.59, 45.66, 45.76, 45.91, 49.95, 66.65, 70.62, 72.67, 74.77. HRMS-ESI m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{32}\text{H}_{71}\text{N}_4\text{O}_2$ 543.5577, found 543.5577.

1.1.5.11. 12-Amino-1-[N-(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)amino]-3,6-diazaoctane tetrahydrochloride (7d)

Yield 74 %. ^1H NMR (300 MHz, CDCl_3 - CD_3OD): 0.87 (t, 3 H, $J = 6.8$ Hz, $(\text{CH}_2)_{15}\text{CH}_3$), 1.19-1.27 (m, 33 H, $(\text{CH}_2)_{15}\text{CH}_3$, OCH_2CH_3), 1.51-1.62 (m, 2 H, OCH_2CH_2), 3.09-3.52 (m, 14 H, 7 CH_2NH), 3.58-3.94 (m, 7H, $\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CHOCH}_2\text{CH}_3$). ^{13}C NMR (75 MHz, CDCl_3): δ 14.57, 15.80, 23.55, 23.65, 26.82, 30.18, 30.29, 30.36, 30.45, 30.63, 30.86, 32.85, 37.31, 39.86, 44.71, 45.73, 45.76, 45.82, 50.28, 66.73, 70.67, 72.69, 74.77. HRMS-ESI m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{65}\text{N}_4\text{O}_2$ 501.5108, found 501.5099.

1.2. Biology

1.2.1. Cell lines and culture conditions

All reagents were from Sigma-Aldrich unless specified otherwise. The HCT116 (colon carcinoma), K562 (chronic myelogenous leukemia), and MCF7 (breast adenocarcinoma) cell lines were from American Type Culture Collection (Manassas, VA). Cells were propagated at 37°C, 5% CO₂ in Dulbecco modified Eagle's medium (HCT116 and MCF7) or RPMI-1640 (K562) media supplemented with 5% fetal bovine serum (HyClone, Logan, UT), penicillin (100 U ml⁻¹), streptomycin (100 µg ml⁻¹) and 2 mM *L*-glutamine.

1.2.2. MTT-assay

The MTT-assay was used to evaluate the cytotoxicity of our compounds. For this purpose, HCT-116, K562, and MCF7 cells were seeded in 96-well plates at a density of 5x10³ cells per well and incubated for 24 h. The cells were then treated with aliquots of lipophilic polyamines solutions in water to reach final concentrations of 0.1; 0.2; 0.4; 0.8; 1.6; 3.2; 6.4; 12.5; 25; 50 µM. After 72 h of incubation at 37°C and 5% CO₂, 20 µl of MTT-solutions [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5 mg ml⁻¹ in distilled water) were added per well, and the plates were incubated for an additional 2 h. The supernatant was removed, DMSO (100 µl) was added to each well, and the plates were mixed to dissolve the formazan crystals. The optical density was measured at 571 nm on Multiscan FC (Thermo Scientific, USA). Finally, the results were processed using GraphPad Prism software version 6. The cytotoxicity data are expressed in IC₅₀ values (concentration that inhibits 50% of cell growth). For each compound, the assay was repeated at least in triplicate.

1.2.3. Hemolysis

To study hemolysis, erythrocytes were obtained from peripheral blood of healthy persons. The blood was collected in test-tubes containing 1% sodium citrate, stirred, and incubated for 1 h at 4 °C. The suspension of erythrocytes was washed with buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.76 mM KH₂PO₄, pH 7.4), the cells were suspended in 50 µl of the same buffer. Tested compounds were added to the final concentrations given in Table S2. The volume of the added solutions of tested glycerolipids did not exceed 10% of a total volume of the mixture. In the control test-tube, distilled water (50 µl) was added to the suspension of erythrocytes. The samples were incubated for 1 h at 37 °C with gentle stirring, then centrifuged at 2000 rpm. Optical density of the supernatant was measured on a LKB spectrophotometer (Sweden) at absorption wavelength $\lambda = 545$ nm. The obtained values of absorption were compared with the hemolysis induced by water (the absorption was taken as 100%).




Table S1. Cytotoxicity of modified polyamines for human tumour cell lines.

Compound	IC ₅₀ ^a , μmol dm ⁻³		
	K562	HCT116	MCF7
6a	1.30 ±0.40	6.20±1.90	5.80±0.93
6b	1.89±0.05	3.29±0.03	1.82±0.41
6c	2.07±1.12	3.21±0.22	1.94±0.12
6d	2.01±0.13	2.97±0.19	1.93±0.48
6e	2.25±0.25	3.83±0.07	1.86±0.31
6f	1.85±0.34	1.64±0.02	1.28±0.24
6g	1.80±0.10	2.70±0.50	n.d. ^b
7a	1.90±0.20	8.50±0.70	2.70±0.93
7b	2.06±0.11	4.23±0.12	1.99±0.36
7c	2.18±0.30	3.33±0.14	2.02±0.44
7d	2.40±0.10	6.80±1.10	n.d.
Edelfosine	32.0±2.0	1.0±0.5	6.5±0.5
CL	17.0±0.60	10.8±0.30	20.4±0.60
DENSpM	>50	>50	>50

^aThe IC₅₀ value represents the concentration that induced 50% cell death after a 72 h exposure;

^bn.d. – no data.

Table S2. Hemolytic effect of lipophilic polyamines.

Compound	Hemolysis ^a (%)
6b	8.8
6c	8.1
6d	6.8
6e	2.9
7b	8.3
6f	4.7
7c	6.3
Edelfosine^{b,c}	18.5
CL^c	2.8
DENSpm	2.9

^aHemolysis caused by resuspension of erythrocytes in pure water was taken as 100%;

^bEdelfosine concentration was 8 $\mu\text{mol dm}^{-3}$

^cE. V. Shmendel, K. A. Perevoshchikova, D. K. Shishova, T. S. Kubasova, L. L. Tyutyunnik, M. A. Maslov, A. A. Shtil, *Russ. Chem. Bull.*, 2015, **64**, 1648.




Figure S1. The impact of the length of the *O*-alkyl chain at the C1 position of the glycerol backbone on polyamines cytotoxicity against (a) colon cancer (HCT116), (b) breast adenocarcinoma (MCF-7), and (c) myelogenous leukaemia (K562) cells. The data are presented as mean values \pm SEM for $n = 3$ experiments. No significant difference in the row C10-C18 was observed by the paired t-test, with the exception of pair 6^b and 6^e against the K562 cells, * $P < 0.1$.








Figure S2. Cytotoxic profiles of **6c**, **6f** and **DENSpm** against HCT 116, K562 and MCF7 cells.



12-Ethylamino-1-[(rac-2-ethoxy-3-octadecyloxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (6a)








12-Ethylamino-1-[(rac-2-ethyloxy-3-hexadecyloxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (6b)








12-Ethylamino-1-[(rac-2-ethoxy-3-tetradecyloxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (6c)








12-Ethylamino-1-[(rac-3-dodecyloxy-2-ethoxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (6d)








12-Ethylamino-1-[(rac-3-decyloxy-2-ethoxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (6e)








11-Ethylamino-1-[(rac-2-ethoxy-3-octadecyloxyprop-1-yl)amino]-4,8-diazaundecane tetrahydrochloride (6f)








8-Ethylamino-1-[(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)amino]-3,6-diazaoctane tetrahydrochloride (6g)








12-Amino-1-[(rac-2-ethoxy-3-octadecyloxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (7a)








12-Amino-1-[(rac-2-ethoxy-3-hexadecyloxyprop-1-yl)amino]-4,9-diazadodecane tetrahydrochloride (7b)





11-Amino-1-[N-(rac-2-ethoxy-3-octadecyloxyprop-1-yl)amino]-4,8-diazaundecane tetrahydrochloride (7c)





8-Amino-1-[N-(rac-2-ethyloxy-3-octadecyloxyprop-1-yl)amino]-3,6-diazaoctane tetrahydrochloride (7d)

